In recent years, oligonucleotides have made remarkable strides as future medicines. The potential of oligonucleotides as treatment for previous untreatable conditions has been realized by the recent regulatory approvals of antisense oligonucleotides (inotersen and golodirsen) and small interfering double stranded RNA (patisiran and givosiran). Additionally, significant progress has been made in emerging technologies such as CRISPR-Cas systems.
Chemistry has played a critical role in the success of therapeutic oligonucleotides. This year mark the approval of first, fully chemically modified small interfering double stranded RNA conjugated to a ligand (N-acetylgalactosamine) by the FDA. This special issue is intended to celebrate the success of chemists and chemistry, and we invite all the researchers in the field of nucleic acids to participate by submitting their novel research work, or sharing their knowledge of the field in the form of review articles.
Submission is still open
Beilstein J. Org. Chem. 2021, 17, 622–629, doi:10.3762/bjoc.17.54
Beilstein J. Org. Chem. 2021, 17, 749–761, doi:10.3762/bjoc.17.65
Beilstein J. Org. Chem. 2021, 17, 891–907, doi:10.3762/bjoc.17.75
Beilstein J. Org. Chem. 2021, 17, 908–931, doi:10.3762/bjoc.17.76